Mandate

Vinge advises IBT on share issues

November 24, 2017

Vinge advises Infant Bacterial Therapeutics AB (publ) (Nasdaq First North Premier) in connection with a combined directed issue and rights offering of approximately SEK 545 million.

The Vinge team includes Erik Sjöman, Christian Lindhé, Kristoffer Franzkeit, Ludvig Frithiof and Astrid Karlsson.

Related

Vinge has advised Behold Ventures in the fundraising of Behold Ventures’ first-time fund

Behold Ventures held its final closing on 27 June 2025, thereby securing investor commitments to its first-time fund amounting to approximately SEK 550 million from an international investor base, comprising the European Investment Fund (EIF), among others.
July 10, 2025

Vinge advises Main Capital in connection with the sale of Alfa eCare

Vinge has advised Main Capital in connection with the sale of Alfa eCare Holding AB and its subsidiaries (“Alfa eCare”) to SDB Groep B.V. (“SDB”)
July 10, 2025

Vinge is advising on the establishment of Ballista Capital

Ballista Capital held its final closing on 9 June 2025. The investor base primarily comprises family offices and investors with strong ties to northern Sweden.
July 07, 2025